Corify Care Wins FDA Nod for Acorys Cardiac Mapping Tech

Corify Care has received U.S. Food and Drug Administration (FDA) clearance for the Acorys system, an imageless, non-invasive cardiac mapping platform that can provide a global, four-chamber view of cardiac electrical activity in real-time.

Acorys introduces true 4D cardiac mapping by combining high-resolution 3D anatomical models with real-time electrical activity. The company said the instant, whole-heart functional insight allows faster, safer, and more predictable ablation procedures.

The system empowers physicians with real-time, panoramic mapping of complex arrhythmia mechanisms. The approach lets clinical teams gather immediate functional insight without needing pre-procedural imaging or induction of unstable arrhythmias.

Acorys’ non-invasive functional mapping complements standard catheter workflows. It can rapidly identify arrhythmogenic substrate, including VT, complex atrial tachyarrhythmias or cardiac desynchronization.

“FDA clearance of ACORYS is a defining moment—not just for Corify, but for the future of electrophysiology,” said Andreu Climent, Ph.D., CEO of Corify Care. “For decades, EP has been limited by incomplete and time-intensive contact based mapping. ACORYS changes the paradigm—by delivering immediate pre-procedural and inter-procedural, global insight that allows physicians to understand complexity, define targets, and act with confidence from the very first beat.”

Corify will now begin a phased U.S. commercial rollout, partnering with leading electrophysiology centers to drive adoption of its next-gen mapping platform.

“ACORYS gives us something we’ve never had before—a complete understanding of the arrhythmia before we even start ablating,” said Felipe Atienza, MD, CMO and co-founder of Corify Care. “This has the potential to dramatically change how we approach complex cases, particularly in VT and Atrial Tachyarrhythmias.”